Emgality (galcanezumab) is a calcitonin gene-related peptide (CGRP) antagonist used primarily as a preventive treatment for migraine, administered once monthly via subcutaneous injection. Nurtec ODT (rimegepant), on the other hand, is a CGRP receptor antagonist that is taken orally and can be used both for the acute treatment of migraine attacks and for preventive treatment, with dosing up to every other day. When deciding between the two, patients should consider factors such as their preference for an injectable versus an oral medication, the frequency of their migraine attacks, and whether they are seeking prevention, acute treatment, or both.
Difference between Emgality and Nurtec ODT
| Metric | Emgality (galcanezumab) | Nurtec ODT (rimegepant) |
|---|---|---|
| Generic name | galcanezumab | rimegepant |
| Indications | Preventive treatment of migraine in adults | Acute treatment of migraine with or without aura in adults |
| Mechanism of action | Calcitonin gene-related peptide (CGRP) antagonist | Calcitonin gene-related peptide (CGRP) receptor antagonist |
| Brand names | Emgality | Nurtec ODT |
| Administrative route | Subcutaneous injection | Orally disintegrating tablet |
| Side effects | Injection site reactions, constipation, itching | Nausea, stomach pain, indigestion, dry mouth |
| Contraindications | Hypersensitivity to galcanezumab or any of the excipients | Hypersensitivity to rimegepant or any of the components of the formulation |
| Drug class | Monoclonal antibody | Small molecule CGRP receptor antagonist |
| Manufacturer | Eli Lilly and Company | Biohaven Pharmaceuticals |
Efficacy
Emgality (Galcanezumab) Efficacy in Migraine Prevention
Emgality (galcanezumab) is a humanized monoclonal antibody that is specifically designed for the prevention of migraine. It works by targeting and blocking the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a crucial role in migraine pathophysiology. Clinical trials have demonstrated that Emgality is effective in reducing the frequency of migraine days in adults with episodic and chronic migraine. Patients treated with Emgality have reported experiencing a significant reduction in monthly migraine days compared to those on placebo. Additionally, some patients achieved at least a 50% reduction in the number of migraine days per month, indicating substantial efficacy for migraine prevention.
Nurtec ODT (Rimegepant) Efficacy in Migraine Treatment
Nurtec ODT (rimegepant) is an orally disintegrating tablet used for the acute treatment of migraine with or without aura in adults. As a CGRP receptor antagonist, Nurtec ODT helps to relieve migraine symptoms by blocking the CGRP receptor, which is believed to play a key role in migraine attacks. Clinical studies have shown that a single dose of Nurtec ODT can provide rapid pain relief, with some patients experiencing relief within just two hours after administration. Furthermore, a significant proportion of patients have reported sustained pain freedom for up to 48 hours post-dose, highlighting its effectiveness in treating migraine attacks.
Comparative Efficacy in Migraine Management
When comparing Emgality and Nurtec ODT, it is important to note that they are used for different aspects of migraine management. Emgality is primarily used as a preventive treatment, aiming to reduce the frequency and severity of migraine episodes over time. On the other hand, Nurtec ODT is designed for the acute treatment of migraine symptoms, providing rapid relief from an ongoing attack. Both medications have shown efficacy in their respective roles, with Emgality being beneficial for long-term management and Nurtec ODT offering prompt symptom relief during acute episodes.
Conclusion
In conclusion, both Emgality (galcanezumab) and Nurtec ODT (rimegepant) have proven to be efficacious in the treatment of migraine, albeit in different capacities. Emgality serves as an effective preventive option, reducing the frequency of migraine days for patients with episodic and chronic migraine. Nurtec ODT, meanwhile, offers significant and rapid relief from the acute symptoms of a migraine attack. The choice between these medications should be based on the individual patient's needs, whether it is ongoing prevention or immediate treatment of symptoms, and should be made in consultation with a healthcare professional.
Regulatory Agency Approvals
Emgality
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA -
Health Canada -
Therapeutic Goods Administration (TGA), Australia
Nurtec ODT
-
Food and Drug Administration (FDA), USA
If Emgality or Nurtec ODT are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
Buy Emgality
Buy Nurtec ODT
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us
